

Background

Dr. Michael F. Rafferty serves as Vice President of Preclinical Development at Deciphera Pharmaceuticals, LLC. Dr. Rafferty joined the medicinal chemistry department at Warner-Lambert/Parke-Davis in Ann Arbor, Michigan. He is an Adjunct Professor of medicinal chemistry at the University of Kansas. Since 2005, he has consulted with large and small pharmaceutical organizations on various discovery and early development programs. He joined Searle as Director of CNS Diseases research, where he was responsible for directing discovery programs targeting pain management, neurological disorders, and GI diseases. He served as Director of CNS medicinal chemistry at Parke-Davis, where he was responsible for over a broad range of neuropsychiatric and neurological diseases research programs. He served as the chair of the exploratory development program for pregabalin (Lyrica) from 1993 to 1997. He served as an Executive Director of the newly created Discovery Technologies department. He was an Adjunct Professor of medicinal chemistry department at the University of Michigan and coeditor-in-chief, Medicinal Research Reviews. He served as a Member of Scientific Advisory Board of Deciphera Pharmaceuticals, LLC. He serves on the editorial board of Molecular Pharmaceutics and has served as ad hoc reviewer for a number of medicinal chemistry and pharmacology journals. He is a treasurer of the Medicinal and Bioorganic Chemistry Foundation, which he co-founded in 1995. He is an inventor on 42 issued US patents and co-author on 56 peer-reviewed papers. Mr. Rafferty holds a Ph.D. in Medicinal Chemistry from the University of Kansas and a postdoctoral fellowship at the NIH.